Robert Peach

USPTO Granted Patents = 43 (Patent Applications = 7)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.9

ph-index = 13

Forward Citations = 775(Granted Patents)

Location History:

Arnold, MD (US) (1976 - 1986)
Edmonds, WA (US) (1998 - 2000)
San Diego, CA (US) (2005 - 2022)

Company Filing History:

34 out of 3,681

Bristol-myers Squibb Compnay

Celgene International Ii Sarl

patents

5. 2 out of 832,680

Other

patents

Years Active: 1976-2024

Loading Chart...

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129294 - Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies (2024-10-29),

2. 12122826 - Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies (2024-10-22),

3. 11390669 - Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies (2022-07-19),

4. 11278526 - Compounds and methods for treating lupus (2022-03-22),

5. 10590183 - BSL2v2c2-Ig polypeptides (2020-03-17),

6. 10400023 - B7-related nucleic acids and polypeptides useful for immunomodulation (2019-09-03),

7. 10370428 - Methods of treatment using CTLA4 mutant molecules (2019-08-06),

8. 10308702 - BSL2v2c2-Ig polypeptides (2019-06-04),

9. 10239846 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis (2019-03-26),

10. 10052360 - Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule (2018-08-21),

11. 9758565 - Methods of treatment using CTLA4 mutant molecules (2017-09-12),

12. 9409970 - Polynucleotides encoding BSL2v2c2 (2016-08-09),

13. 9399052 - Polynucleotides encoding BSL2v2c2-Ig (2016-07-26),

14. 9388147 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis (2016-07-12),

15. 9296808 - Methods for treating scleroderma by administering a soluble CTLA4 molecule (2016-03-29),

Title: The Innovative Contributions of Robert Peach in Biomedical Patents

Introduction

Robert Peach, based in San Diego, CA, is a prominent inventor known for his significant contributions to the field of biomedical research and treatment. With an impressive portfolio of 41 patents, he has dedicated his career to developing innovative methods that address critical health issues.

Latest Patents

Among his most recent inventions are methods for treating diseases characterized by detrimental Interleukin-13 (IL-13) activity. This encompasses conditions such as eosinophilic esophagitis (EoE) and asthma. The innovative approach involves administering a composition that contains an IL-13 antibody or an antigen binding fragment to patients in need of treatment. This dual patent demonstrates the potential to significantly improve therapeutic outcomes for individuals suffering from these challenging diseases.

Career Highlights

Robert Peach has had a distinguished career, working with some of the leading pharmaceutical companies in the industry. Notably, he has contributed to the mission of Bristol-Myers Squibb Company and AbbVie Inc., where he collaborated with top professionals in the field, optimizing drug development and innovation.

Collaborations

Throughout his career, Robert has had the opportunity to work alongside esteemed colleagues, including Glen Eugene Mikesell and Han Chang. These collaborations have been instrumental in bolstering his research efforts and bringing forward promising medical treatments.

Conclusion

Robert Peach stands out as a noteworthy inventor whose work has the potential to transform the way we approach the treatment of diseases related to IL-13. His commitment to innovation and collaboration within the pharmaceutical industry illustrates the vital role that inventors play in advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.